Spyros Papapetropoulos - 01 Mar 2022 Form 4 Insider Report for Vigil Neuroscience, Inc. (VIGL)

Role
Chief Medical Officer
Signature
/s/ Jennifer Ziolkowski, Attorney-in-Fact
Issuer symbol
VIGL
Transactions as of
01 Mar 2022
Net transactions value
$0
Form type
4
Filing time
03 Mar 2022, 15:05:54 UTC
Previous filing
06 Jan 2022
Next filing
12 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIGL Stock Option Grant (Right to Buy) Award $0 +75,500 $0.000000 75,500 01 Mar 2022 Common Stock 75,500 $16.13 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment vesting on April 1, 2022.